Biomarker Panels for Reliable Mild Traumatic Brain Injury Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing mild traumatic brain injury (mTBI) are unreliable and costly, with existing biomarkers like S100B providing high false negatives and insufficient specificity, leading to unnecessary CT scans and potential complications.
Innovation Solution
A combination of biomarkers such as glutathione S transferase Pi (GSTP), fatty-acid-binding protein (FABP), glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), neuromodulin (GAP43), neurofilament proteins (NFH, NFM, NFL), S100B, Tau, ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1), vascular cell adhesion protein 1 (VCAM), serum amyloid A (SAA), Chemokine (C-C motif) ligand 23 (CCL23), peroxiredoxin 1 to 6, and nucleoside diphosphate kinase (NDKA) is used to improve detection and classification of mTBI, achieving high specificity and sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If S100B is used as a biomarker for mTBI detection, then the detection process is simplified, but the specificity and reliability of diagnosis deteriorates due to high false negatives
Solution Approach 1:
The patent combines multiple biomarkers (S100B, GFAP, UCH-L1, NSE, and others) into a panel that works synergistically to improve diagnostic accuracy. By merging the detection capabilities of individual markers, the system achieves both simplified operation and high reliability, as the combination provides complementary information that reduces false negatives while maintaining ease of blood-based detection.
Solution Approach 2:
The invention creates a composite biomarker panel that integrates multiple molecular markers with different detection characteristics. This composite approach leverages the strengths of each individual marker while compensating for their limitations, achieving superior diagnostic reliability without sacrificing operational simplicity.
2Measurement precision
If CT scans are performed to detect cerebral lesions in mTBI patients, then the detection accuracy is improved, but the cost and time consumption increases
Solution Approach 1:
The patent applies preliminary action by using biomarker panels as a screening tool before ordering CT scans. The biomarker panel is performed first to identify patients with high probability of intracranial lesions, and only those with positive results undergo CT scanning. This preliminary screening reduces the number of unnecessary CT scans, thereby reducing time consumption and costs while maintaining high detection accuracy for patients who need imaging.
Solution Approach 2:
The biomarker panel serves as an intermediary between the trauma assessment and CT scanning decisions. It provides a rapid, cost-effective initial evaluation that mediates the decision-making process, allowing clinicians to efficiently triage patients and order CT scans only when clinically indicated, thus reducing overall time consumption without compromising detection accuracy.
3Measurement precision
If CT scans are performed for mTBI patients, then the detection of intracranial lesions is improved, but the cost increases
Solution Approach 1:
The biomarker panel performs a preliminary assessment that identifies patients who truly need CT scanning. By using cost-effective blood tests as a first-line screening tool, the system reduces the quantity of expensive CT scans performed on patients who can be safely discharged without imaging, thereby reducing overall costs while maintaining high detection precision for intracranial lesions in high-risk patients.
Solution Approach 2:
The patent employs inexpensive, readily available blood-based biomarkers as a disposable screening approach before investing in expensive CT scanning. This strategy uses cheap, easily obtainable samples to make critical diagnostic decisions, reducing the overall cost burden while maintaining high detection precision through the synergistic combination of multiple affordable markers.
4Device complexity
If a single biomarker like S100B is used for mTBI detection, then the test is simpler, but the specificity deteriorates leading to false negatives
Solution Approach 1:
The patent merges multiple biomarkers into a panel that maintains test simplicity while significantly improving specificity. The combined panel uses blood-based detection methods that remain relatively simple to administer while the synergistic effect of multiple markers provides high specificity, reducing false negatives and improving measurement precision without substantially increasing complexity.
Solution Approach 2:
The invention creates a composite biomarker system that integrates multiple molecular components with complementary detection characteristics. This composite approach maintains operational simplicity through unified blood-based sampling and processing while achieving superior specificity through the combined diagnostic power of multiple markers working together.
Data Source
AI summary
The invention relates to a combination of biomarkers and their use in brain injury or mild traumatic brain injury (mTBI) detection. The invention also relates to methods of treating the individual diagnosed with a traumatic brain injury (TBI) or a mild traumatic brain injury (mTBI) using such biomarkers.